Fannin Partners has been awarded a $300,000 Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) to advance a first-in-class, non-VEGF–targeted therapeutic for ...
Ollin Biosciences’ VEGF/Ang2 bispecific antibody has shown superiority over Roche’s Vabysmo (faricimab) in a head-to-head ...
Expert Rev Ophthalmol. 2013;8(5):475-484. Together, these preclinical data indicate that both antibody and small kinase-based VEGF/PDGF antagonists are effective in animal models of pathologic ocular ...
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
Please provide your email address to receive an email when new articles are posted on . Faricimab was well-tolerated and had an acceptable safety profile in the phase 3 clinical trial program. Dual ...
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback